NEW YORK (GenomeWeb News) – Stat-Diagnostica today announced that it has raised €17 million ($22.1 million) in a Series B financing round.

The Barcelona, Spain-based firm said that it will use the funds to complete development of its Near Patient Testing diagnostic system and to clinically validate its first products. The test platform combines molecular and immunoassay techniques in a single device and can provide results in less than 30 minutes, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.